Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

Treatment and Diagnosis plans to sponsor Phase I and Phase II trials of PCI-32765 in various hematologic malignancies.
  • The Phase II clinical program, designed to enable potential registrational paths in CLL, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL), is ongoing. We anticipate that these Phase II trials will allow for Phase III enabling decisions in these indications based upon ongoing analysis of the data in the next 6-12 months.

  • As of the end of August, 2011 we enrolled 320 patients into clinical trials evaluating PCI-32765. The ongoing Phase II program currently includes the following studies:
  • PCYC-1104:  A multicenter, Phase II study of PCI-32765 in relapsed or refractory mantle cell lymphoma, including cohorts of subjects either previously treated with bortezomib or naïve to bortezomib treatment. This trial is active in several US and European sites and by the end of August, 2011 enrolled 60 patients. We have submitted a preliminary analysis of this study for consideration for the 2011 ASH meeting in December, 2011.
  • PCYC-1106:  A multicenter, open-label, Phase II study of PCI 32765 in subjects with relapsed or refractory DLBCL. This study is designed to assess the activity of PCI-32765 in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center (GC) subtype. This trial is active in several US sites and by the end of August, 2011 enrolled 13 patients. We expect to complete enrollment of all 60 patients by calendar Q1 2012. A separate pilot study of PCI-32765 in patients with ABC subtype DLBCL is currently being conducted at the NIH Clinical Center. An abstract detailing an interim analysis of this pilot trial has been submitted for consideration for the 2011 ASH meeting in December, 2011.
  • PCYC-1108: A Phase IB, multicenter, open-label, study of PCI 32765, in combination with intensive immune chemotherapy (FCR = fludarabine, cycl
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
    2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
    3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
    4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
    5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
    6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
    7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
    9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
    10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
    11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
    (Date:7/28/2014)... July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, August ... www.isispharm.com How:Live on the Internet. Simply log onto ... participate during the live event, a replay of the ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. ...
    (Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
    Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
    ... , , ... use of stem cells in the treatment of heart failure, ... physicians have performed the world,s first phase-one FDA-approved clinical trial ... The clinical trial is being conducted by a team of ...
    ... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
    Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4
    (Date:7/28/2014)... Top Northridge dentist , Dr. Farshid Ariz, is ... new dentist can be an intimidating experience. Many people struggle ... and worry about how they will connect with a new ... concerns and dental needs and works to ensure that each ... special coupon can help patients get the treatments they need ...
    (Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
    (Date:7/28/2014)... (HealthDay News) -- Following a healthy lifestyle may help ... issues, a new study indicates. Researchers suggested that ... should be educated about how their diet ... future. "These findings are important because they indicate ... have the opportunity to influence their own health outcomes," ...
    (Date:7/28/2014)... Nevada (PRWEB) July 28, 2014 Mahendra ... Trivedi, hosted the Trivedi Online Workshop ‘Consciousness is Power’ ... PM (EST). During this workshop, participants from all over ... importance of making a deeper connection to their inner ... the participants explored the various advantages of raising consciousness ...
    (Date:7/28/2014)... 28, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. More ... its Fort Myers campus, and the company announced that ... is to support several health-insurance clients, which have seasonal ...
    Breaking Medicine News(10 mins):Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4
    ... Hospitals (UH) Case Medical Center is conducting the first ... "heat therapy" or local radiofrequency energy to treat premature ... to the energy produced by radio waves directed with ... a nerve. Premature ejaculation (PE) affects 20 percent ...
    ... Research Institute (LRI) today announced the award of 12 ... drive innovation and discover novel approaches to understand and ... diseases lupus. Awarded for the highest-ranked ... topics and multi-disciplinary approaches that mirror the heterogeneity and ...
    ... Institute (GHI) and Inserm (Institut National de la Sant ... for biomedical research) has discovered that a class of ... in cancer cells also kills the parasite that causes ... new strategy for combating this deadly disease. The ...
    ... leg ulcers is good quality nursing care and the ... University of Leeds has shown that ultrasound therapy does nothing ... contrary to what had been expected. Traditional methods of nursing ... as well, the authors conclude. "The ,healing energy, of ...
    ... might be required for maximum anti-tumor activity when ... studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The ... Proceedings of the National Academy of Sciences ... HER3 receptor limits the effectiveness of two classes ...
    ... An analysis conducted by Ohio State University cancer ... to the treatment of patients with advanced ovarian cancer ... value of various clinical strategies will be published online ... , The researchers performed a cost-effectiveness analysis looking at ...
    Cached Medicine News:Health News:University Hospitals Case Medical Center testing innovative 'heat therapy' for premature ejaculation 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 3Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 4Health News:Malaria's weakest link 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 3
    The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
    348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
    The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
    ... optimal combination of performance and rapid, ... mL swinging bucket rotor. DiscoveryTMM120 SE ... to 8.3 ml, with a small ... quiet operation, rotor imbalance detection, thermo-electric ...
    Medicine Products: